Valuation: Genmab A/S

Market Cap 223B 33.29B 29.86B 27.29B 24.91B 46.94B 3,130B 48.42B 329B 131B 1,670B 125B 122B 5,272B P/E 2026 *
42.3x
P/E 2027 * 31.8x
Enterprise Value 242B 36.05B 32.33B 29.55B 26.98B 50.82B 3,389B 52.43B 356B 142B 1,808B 135B 132B 5,708B EV / Sales 2026 *
8.09x
EV / Sales 2027 * 6.47x
Free-Float
94.3%
Yield 2026 *
-
Yield 2027 * -
1 day-2.97%
1 week-9.84%
Current month-9.84%
1 month+41.82%
3 months+76.44%
6 months+100.57%
Current year+74.00%
1 week 3,435
Extreme 3435
3,871
1 month 2,400
Extreme 2400
3,947
Current year 1,512
Extreme 1512
3,947
1 year 1,512
Extreme 1512
3,947
3 years 1,157
Extreme 1157
3,947
5 years 1,157
Extreme 1157
3,947
10 years 786.2
Extreme 786.2
3,947
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/25 A Exercice

Director

189 0.0003%
12/1/25 A Exercice

Director

189 0.0003%
12/1/25 A Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-2.97%-9.84%+90.91%+73.49% 33.29B
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
+5.19%+1.62%-39.69%+368.87% 25.1B
-2.18%+7.06%+40.97%-3.11% 24.92B
Average +0.80%+3.09%+48.36%+167.08% 43.16B
Weighted average by Cap. +0.49%+3.30%+49.39%+156.12%

Financials

2026 *2027 *
Net sales 29.89B 4.46B 4B 3.65B 3.34B 6.28B 419B 6.48B 44.04B 17.56B 224B 16.73B 16.37B 706B 36.26B 5.41B 4.85B 4.43B 4.05B 7.62B 508B 7.86B 53.43B 21.31B 271B 20.3B 19.86B 856B
Net income 5.12B 764M 685M 626M 572M 1.08B 71.83B 1.11B 7.55B 3.01B 38.33B 2.87B 2.81B 121B 7.31B 1.09B 978M 894M 816M 1.54B 103B 1.59B 10.78B 4.3B 54.72B 4.09B 4.01B 173B
Net Debt 18.49B 2.76B 2.47B 2.26B 2.06B 3.89B 259B 4.01B 27.24B 10.86B 138B 10.35B 10.13B 437B 11.29B 1.68B 1.51B 1.38B 1.26B 2.37B 158B 2.45B 16.63B 6.63B 84.43B 6.32B 6.18B 267B
Projected Income Statement - Annual - Genmab A/S
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,244
Date Price Change Volume
06/11/26 DKK 3,527.00 -2.97% 259,891
05/11/26 DKK 3,635.00 +1.59% 178,776
04/11/26 DKK 3,578.00 -3.79% 199,589
03/11/26 DKK 3,719.00 +0.57% 184,682
02/11/26 DKK 3,698.00 -5.47% 271,367
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Genmab A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
3,527.00DKK
Average target price
4,007.00DKK
Spread / Average Target
+13.61%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Genmab A/S
  1. Stock Market
  2. Stocks
  3. GMAB Stock